Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience

EKENEL M., Karabulut S., Cil I., Zirtiloglu A., Aydin E., Tural D.

ACTAS UROLOGICAS ESPANOLAS, cilt.44, sa.1, ss.27-33, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.acuro.2019.06.007
  • Dergi Adı: ACTAS UROLOGICAS ESPANOLAS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Gender Studies Database, MEDLINE, DIALNET
  • Sayfa Sayıları: ss.27-33
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: Sunitinib (SUN) and pazopanib (PAZ) are 2 oral tyrosine kinase inhibitors against vascular endothelial growth factor. Their efficacy and safety in metastatic renal cell carcinoma has been proven with phase iii studies. However, real world data is limited. The objective of this study is to assess the clinical benefit of SUN and PAZ in routine practice.